End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.8 INR | -3.00% |
|
-6.05% | -20.82% |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net sales 1 | 116.9 | 283.8 | 370.9 | 331.4 |
EBITDA 1 | 4.413 | 9.591 | 13.92 | 22.98 |
EBIT 1 | 3.363 | 8.308 | 12.84 | 22.48 |
Operating Margin | 2.88% | 2.93% | 3.46% | 6.78% |
Earnings before Tax (EBT) 1 | 0.481 | 1.691 | 5.509 | 13.18 |
Net income 1 | 0.199 | 0.951 | 3.509 | 9.436 |
Net margin | 0.17% | 0.34% | 0.95% | 2.85% |
EPS 2 | 0.0379 | 0.1895 | 0.7105 | 1.666 |
Free Cash Flow | - | -14.88 | -4.744 | -412.6 |
FCF margin | - | -5.24% | -1.28% | -124.5% |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 4/12/23 | 4/12/23 | 4/12/23 | 8/22/23 |
Balance Sheet Analysis
Fiscal Period: March | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net Debt 1 | 59.8 | 59.1 | 61.9 | 395 |
Net Cash position 1 | - | - | - | - |
Leverage (Debt/EBITDA) | 13.55 x | 6.159 x | 4.45 x | 17.19 x |
Free Cash Flow | - | -14.9 | -4.74 | -413 |
ROE (net income / shareholders' equity) | - | 3.33% | 8.8% | 10.5% |
ROA (Net income/ Total Assets) | - | 5.21% | 6.27% | 3.65% |
Assets 1 | - | 18.26 | 56 | 258.5 |
Book Value Per Share 2 | 4.110 | 7.520 | 8.690 | 11.10 |
Cash Flow per Share 2 | 0.7200 | 0.3500 | 0.5000 | 0.3400 |
Capex 1 | 5.33 | 0.64 | 0.14 | 6.33 |
Capex / Sales | 4.56% | 0.23% | 0.04% | 1.91% |
Announcement Date | 4/12/23 | 4/12/23 | 4/12/23 | 8/22/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-20.82% | 8.2M | |
+54.61% | 811B | |
+44.25% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+18.45% | 246B | |
+2.09% | 225B | |
+13.03% | 218B | |
+8.61% | 168B |
- Stock Market
- Equities
- MONOPHARMA Stock
- Financials Mono Pharmacare Limited